J Stroke Cerebrovasc Dis. 2009 Nov-Dec;18(6):411-5. doi: 10.1016/j.jstrokecerebrovasdis.2009.08.001.
Stroke is the third-leading cause of death in the United States, Canada, Europe, and Japan. According to the American Heart Association and the American Stroke Association, 750,000 new strokes occur each year, resulting in 200,000 deaths (or 1 of every 16 deaths) per year in the United States alone. Endovascular therapy for patients with acute ischemic stroke is an area of intense investigation. The American Stroke Association has given a qualified endorsement of intra-arterial (IA) thrombolysis in selected patients. IA thrombolysis has been studied in 2 randomized trials and numerous case series. Although 2 devices have been granted FDA 3 approval with an indication for mechanical stroke thrombectomy, none of these devices has demonstrated efficacy in improving patient outcomes. This report defines what constitutes adequate training to perform neuroendovascular procedures in patients with acute ischemic stroke and identifies the performance standards that should be adopted to assess outcomes. These guidelines have been written and approved by multiple neuroscience societies that historically have been directly involved in the medical, surgical, and endovascular care of patients with acute stroke, including the Neurovascular Coalition and its participating societies: the Society of NeuroInterventional Surgery; American Academy of Neurology; American Association of Neurological Surgeons, Cerebrovascular Section; and Society of Vascular & Interventional Neurology.
中风是美国、加拿大、欧洲和日本的第三大死亡原因。根据美国心脏协会和美国中风协会的数据,每年有 75 万例新的中风发生,仅在美国每年就有 20 万人因此死亡(即每 16 例死亡中就有 1 例)。急性缺血性中风患者的血管内治疗是一个研究热点。美国中风协会对选择性患者的动脉内(IA)溶栓给予了有条件的认可。IA 溶栓已在 2 项随机试验和多项病例系列研究中进行了研究。尽管已有 2 种设备获得了美国食品和药物管理局(FDA)对机械性卒中取栓术的 3 级批准,但这些设备均未能证明在改善患者预后方面的有效性。本报告定义了在急性缺血性中风患者中进行神经血管内手术所需的充分培训,并确定了应采用的评估结果的绩效标准。这些指南由多个神经科学学会撰写和批准,这些学会历史上一直直接参与急性中风患者的医疗、手术和血管内治疗,包括神经血管联盟及其参与的学会:神经介入外科学会;美国神经病学学会;美国神经外科学会,脑血管分会;和血管与介入神经病学学会。